Introduction
As a global health crisis, COVID-19 pandemic has been the most serious
challenge to deliver timely care to patients with other
conditions1. Intracerebral hemorrhage (ICH), as a
neurological emergency, is one of the most devastating diseases
worldwide and would require emergency medical care in specialized
neurological intensive care unit (NICU)2. However, it
is difficult to balance between ICH treatment and COVID prevention
during COVID-19 pandemic.
Moreover, hypertension management may be a problem. An unproven notion
before that ACE-1 inhibitors and ARBs might increase the risk of
COVID-19 infection theoretically since increased ACE-2 activity led to
practical medicine restriction. Recently there have been reports that
discontinuation of ACEI/ARB in COVID-19 patients is not related to
severity of COVID-193, 4. However, discontinuation of
ACEI/ARB once was not an uncommon phenomenon. Besides during COVID-19
pandemic the public may also suffered from social pressure, anxiety,
depressed economy, lack of public health resources and so on.
Herein, we compared the differences of ICH manifestations, major
interventions and outcomes between before and during COVID-19 pandemic
at 31 centers in China, from the CHEERY study: Chinese cerebral
hemorrhage: mechanism and intervention study.
Methods
Study design The underlying data for this analysis was collected prospectively of
two groups of patients with ICH before (1/12/2018-30/11/2019) and during
COVID-19 (1/12/2019-30/11/2020) pandemic at 31 centers in China. We
followed the Strengthening the Reporting of Observational Studies in
Epidemiology reporting guideline.